# Resolvyx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resolvyx-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.resolvyx.com
- Total disclosed funding: $32M
- Latest round: Series B (Aug 22, 2008)
- Investors on record: 6

## About

Resolvyx Pharmaceuticals focuses on developing innovative therapies targeting inflammatory diseases, aiming to improve patient outcomes through advanced scientific research and product development.Founded in 2005, Resolvyx Pharmaceuticals operates in Cambridge, US, specializing in the formulation of therapeutic solutions for inflammatory conditions. In January 2011, the company was acquired by Celtic Therapeutics, marking a significant shift in its business strategy. The company has engaged in a total of five investment rounds, with its latest funding being a Series B round amounting to USD 4.00 mn, which included investors such as Atlas Venture and Biogen Idec New Ventures.Resolvyx Pharmaceuticals offers innovative therapies designed for the treatment of inflammatory diseases. Their product range focuses on novel drug formulations that target specific inflammatory pathways, enabling a precision medicine approach to patient care. Through extensive research and clinical trials, the company aims to deliver effective treatments that enhance the quality of life for patients suffering from chronic inflammatory conditions.Resolvyx Pharmaceuticals operates on a transactional revenue model primarily through drug sales and licensing agreements. Their pricing structure is clearly defined, with products available for competitive market prices aligned with industry standards. Currently, the company focuses on capturing value from their innovative drug therapies, ensuring a sustainable financial model through strategic partnerships and clinical advancements.Resolvyx Pharmaceuticals plans to leverage recent funding from their Series B round to advance the development and launch of new therapeutic products aimed at treating inflammatory diseases. The company is exploring opportunities to expand its market presence into Europe and Asia by 2015, aiming to establish strategic partnerships that facilitate this expansion. The funding will also support ongoing clinical trials and product development initiatives, enhancing their portfolio and market reach.

## Funding rounds

- Series B, Aug 22, 2008, $4M — Atlas Venture, CHL Medical Partners, Flagship Pioneering, Radius Ventures, Biogen Idec New Ventures, QVT funds
- Series B, Apr 22, 2008, $25M — Atlas Venture, CHL Medical Partners, Flagship Pioneering, Radius Ventures, Biogen Idec New Ventures, QVT funds
- Series A, Nov 14, 2005, $3M — Atlas Venture, CHL Medical Partners, Flagship Pioneering

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series A, Series B
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Radius Ventures (https://capitalatlas.ai/funds/radius-ventures) — Series B
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series B
- QVT funds — Series B